CASI Pharmaceuticals, Inc. (CASI): Price and Financial Metrics


CASI Pharmaceuticals, Inc. (CASI): $1.24

0.08 (+6.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CASI to Watchlist
Sign Up

Industry: Biotech


Ranked

of 499

in industry

CASI POWR Grades


  • Value is the dimension where CASI ranks best; there it ranks ahead of 61.39% of US stocks.
  • CASI's strongest trending metric is Momentum; it's been moving down over the last 31 weeks.
  • CASI's current lowest rank is in the Quality metric (where it is better than 3.92% of US stocks).

CASI Stock Summary

  • The ratio of debt to operating expenses for CASI Pharmaceuticals Inc is higher than it is for about just 7.24% of US stocks.
  • As for revenue growth, note that CASI's revenue has grown 131.8% over the past 12 months; that beats the revenue growth of 95.24% of US companies in our set.
  • CASI Pharmaceuticals Inc's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -44.5%, greater than the shareholder yield of just 6.36% of stocks in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to CASI Pharmaceuticals Inc are SGLB, PTE, APDN, GTYH, and DCPH.
  • Visit CASI's SEC page to see the company's official filings. To visit the company's web site, go to www.casipharmaceuticals.com.

CASI Valuation Summary

  • In comparison to the median Healthcare stock, CASI's EV/EBIT ratio is 107.87% lower, now standing at -2.1.
  • CASI's price/sales ratio has moved down 51.9 over the prior 243 months.
  • CASI's price/sales ratio has moved down 51.9 over the prior 243 months.

Below are key valuation metrics over time for CASI.

Stock Date P/S P/B P/E EV/EBIT
CASI 2014-05-28 NA 3.6 -8.2 -5.8
CASI 2012-06-15 23.1 18.5 -8.1 -11.6
CASI 2012-01-20 5.3 13.1 -3.5 -3.9
CASI 2008-12-05 3.1 2.8 -0.9 -1.3
CASI 2007-12-14 16.5 4.1 -4.8 -4.7
CASI 2006-11-13 21.7 4.2 -3.2 -2.9

CASI Growth Metrics

  • Its 5 year net cashflow from operations growth rate is now at -325.67%.
  • Its 4 year revenue growth rate is now at 31312.02%.
  • Its 4 year price growth rate is now at 41.46%.
Over the past 49 months, CASI's revenue has gone up $17,471,000.

The table below shows CASI's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-03-31 17.471 -29.253 -53.729
2020-12-31 15.141 -25.886 -48.287
2020-09-30 11.663 -22.672 -46.987
2020-06-30 10.208 -20.59041 -39.68
2020-03-31 7.537 -22.65823 -46.29917
2019-12-31 4.131 -23.243 -46.032

CASI Price Target

For more insight on analysts targets of CASI, see our CASI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $4.20 Average Broker Recommendation 1.25 (Strong Buy)

CASI Stock Price Chart Interactive Chart >

Price chart for CASI

CASI Price/Volume Stats

Current price $1.24 52-week high $3.90
Prev. close $1.16 52-week low $1.14
Day low $1.16 Volume 463,100
Day high $1.24 Avg. volume 1,242,649
50-day MA $1.48 Dividend yield N/A
200-day MA $2.14 Market Cap 173.35M

CASI Pharmaceuticals, Inc. (CASI) Company Bio


CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, acquires, develops, and commercializes therapeutics addressing cancer and other unmet medical needs in China. The company was founded in 1991 and is based in Rockville, Maryland.


CASI Latest News Stream


Event/Time News Detail
Loading, please wait...

CASI Latest Social Stream


Loading social stream, please wait...

View Full CASI Social Stream

Latest CASI News From Around the Web

Below are the latest news stories about CASI Pharmaceuticals Inc that investors may wish to consider to help them evaluate CASI as an investment opportunity.

Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI)

Oppenheimer analyst Leland Gershell assigned a Buy rating to CASI Pharmaceuticals (CASI) today and set a price target of $5.00. The post Oppenheimer Assigns a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst .

Smarter Analyst | June 10, 2021

Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI)

In a report released today, Difei Yang from Mizuho Securities maintained a Buy rating on CASI Pharmaceuticals (CASI), with a price target of The post Mizuho Securities Keeps a Buy Rating on CASI Pharmaceuticals (CASI) appeared first on Smarter Analyst .

Smarter Analyst | June 10, 2021

CASI Pharmaceuticals Announces Dosing Of First Patient Of CID-103 In Phase 1 Clinical Trial For Relapsed Or Refractory Multiple Myeloma

ROCKVILLE, Md. and BEIJING, June 10, 2021 /PRNewswire/ -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, today announced First-Patient-In in the Phase 1 dose

PR Newswire | June 10, 2021

Need To Know: CASI Pharmaceuticals, Inc. (NASDAQ:CASI) Insiders Have Been Buying Shares

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...

Yahoo | June 10, 2021

CASI Pharmaceuticals, Inc. To Participate In Jefferies Virtual Healthcare Conference

CASI Pharmaceuticals, Inc. (Nasdaq: CASI), a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that Dr. Wei-Wu He , Chairman and Chief Executive Officer of CASI Pharmaceuticals, will be presenting at the Jefferies Virtual Healthcare Conference

BioSpace | May 26, 2021

Read More 'CASI' Stories Here

CASI Price Returns

1-mo -17.33%
3-mo -27.91%
6-mo -63.95%
1-year -35.75%
3-year -83.08%
5-year 9.73%
YTD -57.97%
2020 -4.53%
2019 -23.13%
2018 23.69%
2017 182.61%
2016 19.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7641 seconds.